Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 10.7% – Should You Sell?

Posted by Stanley Muller on May 15th, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) shares fell 10.7% during mid-day trading on Friday . The stock traded as low as $9.74 and last traded at $9.5860. 358,762 shares were traded during trading, a decline of 59% from the average session volume of 866,367 shares. The stock had previously closed at $10.74.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KYTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. JPMorgan Chase & Co. reduced their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, HC Wainwright increased their price target on shares of Kyverna Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.00.

Check Out Our Latest Stock Analysis on KYTX

Kyverna Therapeutics Stock Performance

The stock’s 50 day moving average price is $9.03 and its 200 day moving average price is $8.38. The company has a current ratio of 8.15, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13. The firm has a market cap of $567.84 million, a PE ratio of -2.84 and a beta of 2.05.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. As a group, equities analysts forecast that Kyverna Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of large investors have recently added to or reduced their stakes in KYTX. Adage Capital Partners GP L.L.C. acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $15,667,000. AIGH Capital Management LLC acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $14,100,000. Balyasny Asset Management L.P. acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $9,220,000. Propel Bio Management LLC acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $6,267,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $5,640,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

(Get Free Report)

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.